Navigation Links
Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
Date:3/1/2012

SUNNYVALE, Calif., March 1, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, today announced that senior management will host a conference call on Thursday, March 15th, at 1:30 pm PST to discuss the company's second quarter fiscal 2012 financial and operational results as previously announced.Conference Call Details: Date: Thursday March 15, 2012Time: 1:30 pm PSTListen via Internet: http://ir.pharmacyclics.com/events.cfmToll-free: +1-877-407-8133International: +1-201-689-8040The webcast replay will be available for 30 days on the Investor Relations section of the company's Web site at www.pharmacyclics.com.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short ... to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the American ...
(Date:8/18/2017)... ... 18, 2017 , ... Radabaugh & Associates, a family managed ... North-Central West Virginia, is embarking on a cooperative charity effort with the Chestnut ... The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates Insurance Agency, ... commercial clients in the greater Houston region, is helping locally recognized nonprofit Addi’s ... against cancer. , Founded by Tony and Amber Bender after losing their young ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... says will lift the veil on false teachings pertaining to the mother of the Savior ... teach, you see a far different picture of the role of this historical woman. ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: A ... a couple that grew stronger together through the faith they shared to overcome struggles ... is the creation of published author, Barbara J. Corcoran, a retired teacher and happily ...
Breaking Medicine News(10 mins):